CardiASK tabs 100mg #60

Instruction for CardiASK

Reed more and buy CardiASK on this page

CardiASK is a non-steroidal anti-inflammatory drug (NSAID), an antiplatelet agent.

Release form and composition

Dosage form CardiASK - enteric-coated tablets: round, convex on both sides, white, with a smooth shiny surface, slight roughness is possible (10 pcs. In blister packs, in a cardboard box 1, 2 or 3 packs).
Active ingredient: acetylsalicylic acid, in 1 tablet - 50 or 100 mg.
Additional components: plasdon K-90, plasdon S-630, microcrystalline cellulose, calcium stearate, lactose, tween-80, collikut MAE 100P, talc, titanium dioxide, propylene glycol, corn starch, castor oil.

Pharmacological properties

CardiASK is characterized by antiaggregatory action. It also has antipyretic, analgesic and anti-inflammatory properties.

Pharmacodynamics

The mechanism of the antiplatelet action of acetylsalicylic acid (ASA) is the irreversible inhibition of cyclooxygenase (COX-1). This leads to suppression of platelet aggregation and suppression of thromboxane A2 synthesis. The antiplatelet effect is most pronounced in the effect on platelets, which lose the ability to re-synthesize cyclooxygenase. The duration of the antiplatelet effect is approximately 7 days after a single dose, and it is more pronounced in male patients than in women.
ASA increases the fibrinolytic activity of blood plasma and reduces the content of vitamin K-dependent coagulation factors (X, IX, VII, II).

Pharmacokinetics

After oral administration, ASA is rapidly and almost completely absorbed from the gastrointestinal tract, while being partially metabolized during absorption. During and after absorption, the active component of CardiASK passes into the main metabolite - salicylic acid, which is metabolized in the liver under the influence of enzymes. As a result, metabolites such as salicyluric acid, glucuronide salicylate and phenyl salicylate are formed, which are found in urine and many tissues.
In female patients, metabolic processes proceed more slowly due to the weaker activity of enzymes in the blood serum. The maximum content of ASA in blood plasma is recorded 10-20 minutes after oral administration, salicylic acid - in 0.3-2 hours. Since the tablets are acid-resistant, the release of ASA does not occur in the stomach (the tablet coating effectively prevents the drug from dissolving), but in the duodenum with its alkaline environment. For this reason, absorption of ASA in the form of enteric-coated tablets is slowed down within 3-6 hours compared to conventional uncoated tablets.
Salicylic acid and ASA bind intensively to blood plasma proteins (by 66–98%, depending on the dose) and are rapidly distributed in the body's systems. Salicylic acid crosses the placental barrier and is excreted in breast milk.
The excretion of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. The half-life reaches 2-3 hours when taking ASA in small doses and 15 hours when taking the drug in high doses (usually when used as an analgesic). Unlike other salicylates, repeated administration of the drug does not lead to the accumulation of non-hydrolyzed ASA in the blood serum. Salicylic acid and its metabolites are excreted in the urine. In patients with normal renal function, 80-100% of the dose of CardiASK taken once is excreted through the kidneys within 24-72 hours.

Indications for use

According to the instructions, CardiASK is used to prevent the following diseases:
    Transient disorders of cerebral circulation;
    Stroke, including in patients with transient cerebrovascular accidents;
    Thromboembolism after surgery and invasive interventions on the vessels, including angioplasty and endarterectomy of the carotid arteries, coronary arteries and arteriovenous bypass grafting;
    Deep vein thrombosis, thromboembolism of the pulmonary artery and its branches, including with prolonged immobilization of the patient due to extensive surgical intervention;
    Acute myocardial infarction in patients with risk factors such as diabetes mellitus, arterial hypertension, hyperlipidemia, obesity, old age, smoking;
    Recurrent myocardial infarction.
Also, CardiASK is used to treat unstable angina pectoris.

Contraindications

    Hepatic / renal impairment;
    Gastrointestinal bleeding;
    Erosive and ulcerative lesions of the gastrointestinal tract;
    Hemorrhagic diathesis;
    Aspirin triad (combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses with intolerance to acetylsalicylic acid or other NSAIDs);
    Bronchial asthma caused by the intake of salicylates and NSAIDs;
    The simultaneous use of methotrexate at a dose of 15 mg per week or more;
    Age under 18;
    I and III trimester of pregnancy;
    Lactation;
    Hypersensitivity to acetylsalicylic acid or other NSAIDs.
Relative (diseases and conditions requiring caution when using CardiASK due to the risk of complications):
    Gout;
    Hyperuricemia;
    A history of ulcerative lesions of the gastrointestinal tract or intestinal bleeding;
    Bronchial asthma;
    Chronic respiratory diseases;
    Polyposis of the nasal mucosa;
    Hay fever;
    Allergic reactions to drugs;
    Vitamin K deficiency;
    Deficiency of glucose-6-phosphate dehydrogenase;
    Concomitant use of methotrexate at a dose of less than 15 mg per week;
    II trimester of pregnancy.

Instructions for the use of CardiASK: method and dosage

CardiASK should be taken orally before meals with plenty of fluids.
Recommended doses:
    Prophylaxis for suspected acute myocardial infarction: 100-200 mg per day or 300 mg every other day (it is recommended to chew the first tablet so that it is quickly absorbed);
    Prevention of acute myocardial infarction in the presence of risk factors: 100 mg per day or 300 mg every other day;
    Unstable angina pectoris, as well as prevention of repeated myocardial infarction, stroke, transient cerebrovascular accident, thromboembolic complications after invasive studies or surgical interventions on the vessels: 100-300 mg per day;
    Prevention of deep vein thrombosis, thromboembolism of the pulmonary artery and its branches: 100-200 mg per day or 300 mg every other day.
The duration of therapy is determined individually, but the drug is used for a long time.

Side effects

    Respiratory system: bronchospasm;
    Hematopoietic system: increased bleeding; rarely - anemia;
    Digestive system: pain in the abdomen, increased activity of hepatic transaminases, heartburn, nausea, vomiting, ulcers of the gastric mucosa and 12 duodenal ulcers (including with perforation), gastrointestinal bleeding;
    Central nervous system: tinnitus, dizziness;
    Allergic reactions: urticaria, anaphylactic reactions, Quincke's edema.

Overdose

Salicylate intoxication (occurs when taking ASA in daily doses exceeding 100 mg / kg for more than 2 days) can be the result of prolonged use of the drug in toxic doses in the case of an incorrectly prescribed therapeutic regimen (chronic intoxication) or a single accidental or deliberate intake a toxic dose of a drug for a child or an adult (acute intoxication).
Signs of chronic intoxication with salicylic acid derivatives are not specific and are often difficult to diagnose. Mild intoxication usually occurs only after repeated administration of ASA in significant doses and is expressed in hearing loss, tinnitus, headache, dizziness, excessive sweating, nausea and vomiting, and impaired consciousness. After reducing the dose of CardiASK, this symptomatology disappears. Tinnitus can manifest itself at plasma ASA levels of 150–300 μg / ml. More severe symptoms are recorded when the ASA level in blood plasma exceeds 300 μg / ml.
A characteristic sign of acute intoxication is a severe violation of the acid-base balance, the symptoms of which differ depending on the severity of the intoxication and the age of the patient. In children, metabolic acidosis is a typical sign.
Treatment of intoxication is carried out in accordance with approved standards, and its direction is determined by the clinical picture and the severity of intoxication. Therapy is aimed primarily at removing CardiASK from the body and restoring the acid-base state and water-electrolyte balance. Overdose is considered especially dangerous in elderly patients.
Overdose symptoms of mild to moderate severity include respiratory alkalosis, tachypnea, hyperventilation, excessive sweating, profuse sweating, headache, dizziness, hearing loss, tinnitus, blurred consciousness, nausea, vomiting.
As a treatment, gastric lavage, repeated intake of activated carbon, restoration of the acid-base state and water-electrolyte balance, forced alkaline diuresis are recommended.
Symptoms of a moderate to severe overdose are:
    neurological disorders [inhibition of central nervous system functions (confusion, convulsions, drowsiness, coma) and toxic encephalopathy];
    tinnitus, deafness;
    respiratory disorders (asphyxia, hyperventilation, depression of the respiratory center, noncardiogenic pulmonary edema);
    hyperpyrexia;
    respiratory alkalosis accompanied by compensatory metabolic acidosis;
    hematological disorders (hypoprothrombinemia, prolongation of prothrombin time, a number of conditions from inhibition of platelet aggregation to coagulopathy);
    dysfunction of the cardiovascular system (suppression of cardiac activity, lowering blood pressure, arrhythmias);
    gastrointestinal bleeding;
    violations of water and electrolyte balance (dehydration);
    impaired glucose metabolism [ketoacidosis, hypoglycemia (often in children), hyperglycemia];
    renal dysfunction from oliguria to the onset of renal failure, accompanied by hyponatremia, hypernatremia, hypokalemia.
In this case, the patient is immediately admitted to a specialized hospital for emergency therapy, which consists in gastric lavage, repeated intake of activated carbon, restoration of the acid-base state and water-electrolyte balance, hemodialysis, forced alkaline diuresis and the appointment of symptomatic therapy.

Special instructions

CardiASK can cause bronchospasm, asthma attack and other hypersensitivity reactions. Patients with the following diseases are at risk: a history of bronchial asthma, chronic respiratory diseases, polyposis of the nasal mucosa, hay fever, allergic reactions to other drugs (manifested, inter alia, by skin rashes, itching, urticaria).
Taken in high doses, the drug can cause gout in predisposed patients (i.e., in patients with reduced uric acid excretion).
Patients receiving acetylsalicylic acid are at risk of gastrointestinal bleeding, and bleeding of varying degrees during and after surgery.
Patients with diabetes mellitus undergoing hypoglycemic therapy should bear in mind that ASA in high doses can have a hypoglycemic effect.
During treatment, it is recommended to refrain from drinking alcohol, since ethanol increases the risk of damage to the mucous membrane of the gastrointestinal tract and lengthening the bleeding time.

Influence on the ability to drive vehicles and complex mechanisms

Reception of CardiASK does not affect the ability to drive vehicles and perform work associated with increased concentration of attention and rapid psychomotor reactions.

Application during pregnancy and lactation

Reception of CardiASK in high doses in the first trimester of pregnancy increases the risk of fetal defects (heart defects, cleft palate), therefore, its appointment during this period is contraindicated. In the second trimester of pregnancy, salicylates are prescribed only after a careful correlation of the benefits to the mother and the potential risk to the fetus, mainly in daily doses of no more than 150 mg and for a short period of time.
In the third trimester of pregnancy, CardiASK in high doses (more than 300 mg per day) can provoke increased bleeding in the mother and the fetus, early closure of the ductus arteriosus in the fetus, inhibition of labor, and taking the drug immediately before childbirth often leads to intracranial hemorrhages, especially in premature babies children. Therefore, the use of the drug during this period is prohibited.
ASA and its metabolites in small concentrations pass into breast milk. Accidental intake of the drug during breastfeeding does not cause adverse reactions in the child and does not require the cancellation of feedings. However, with long-term therapy or taking CardiASK in high doses, lactation should be stopped immediately.

With impaired renal function

The drug is contraindicated in severe renal failure (CC less than 30 ml / min). In case of renal dysfunction with CC more than 30 ml / min, the drug is used with caution.

For violations of liver function

The drug is not prescribed for class B and higher liver failure in accordance with the Child-Pugh scale. With liver dysfunctions below class B in accordance with this scale, it must be taken with caution.

Drug interactions

    Methotrexate: its renal clearance decreases, due to which the effects of methotrexate are enhanced; the incidence of side effects from the hematopoietic organs increases;
    Digoxin: the concentration in the blood plasma increases, the effects are enhanced;
    Heparin, indirect anticoagulants, thrombolytic and antiplatelet drugs (including ticlopidine), hypoglycemic agents (insulin and sulfonylurea derivatives), valproic acid: their effect is enhanced;
    Uricosuric drugs (including benzbromarone): their effect is weakened;
    Ethanol: additive effect noted;
    Glucocorticosteroids (GCS): excretion increases and the effect of acetylsalicylic acid weakens, and after the abolition of GCS, the risk of ASA overdose increases;
    Anticoagulants, thrombolytics, antiplatelet drugs: the risk of bleeding increases;
    Ibuprofen: the effectiveness of ASA decreases.

Terms and conditions of storage

Store at temperatures up to 25 ° C in a place out of the reach of children, protected from light and moisture.
Shelf life is 2 years.

Reviews

According to reviews, CardiASK is effective and has a pronounced therapeutic effect. However, it is not possible to compare the effectiveness of the drug and its analogues. Also, patients like its low cost.
Experts also speak well of the drug. Very often, CardiASK is prescribed for the prevention of thrombosis of various etiologies, stroke and myocardial infarction.

Terms of sell

You don't need a prescription to buy CardiASK.